Furthermore, persister cancer cells able to tolerate BRAF and MEK inhibitors performed a reversible translation reprogramming which benefited survival, resulting from an increased N6‐methyladenosine (m6A) modification in the untranslated regions of a subset of mRNAs (Shen et al, 2019, 2020). This evidence concerns the gene BRAF and cancer.